Literature DB >> 33459712

Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer's Disease.

Kejing Lao1, Ruisan Zhang1, Jing Luan1, Yuelin Zhang1, Xingchun Gou1.   

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease that has been recognized as one of the most intractable medical problems with heavy social and economic costs. Amyloid-β (Aβ) has been identified as a major factor that participates in AD progression through its neurotoxic effects. The major mechanism of Aβ-induced neurotoxicity is by interacting with membrane receptors and subsequent triggering of aberrant cellular signaling. Besides, Aβ transporters also plays an important role by affecting Aβ homeostasis. Thus, these Aβ receptors and transporters are potential targets for the development of AD therapies. Here, we summarize the reported therapeutic strategies targeting Aβ receptors and transporters to provide a molecular basis for future rational design of anti-AD agents.

Entities:  

Keywords:  Aβ receptor; Aβ transporter; EphB2; LRP-1; LilrB2; NgR; PrPc; RAGE; p75NTR

Year:  2021        PMID: 33459712     DOI: 10.3233/JAD-200851

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

Review 1.  The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease.

Authors:  Yan-Li Zhang; Juan Wang; Zhi-Na Zhang; Qiang Su; Jun-Hong Guo
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

2.  Aβ Influx into the Blood Evoked by Different Blood Aβ Removal Systems: A Potential Therapy for Alzheimer's Disease.

Authors:  Nobuya Kitaguchi; Kazunori Kawaguchi; Miwa Sakata; Hiroki Aoki; Kazunori Yamazaki; Megumi Kaneko; Jun Kinomura; Masao Kato; Midori Hasegawa; Nobuo Suzuki; Masao Mizuno; Yukio Yuzawa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-13       Impact factor: 2.570

3.  The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism.

Authors:  Yan Xu; Dorothea Robev; Nayanendu Saha; Bingcheng Wang; Matthew B Dalva; Kai Xu; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Mol Sci       Date:  2021-09-28       Impact factor: 5.923

Review 4.  ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.

Authors:  Grant A Krafft; Jasna Jerecic; Eric Siemers; Erika N Cline
Journal:  Front Neurosci       Date:  2022-04-26       Impact factor: 5.152

5.  Docking and Molecular Dynamics-Based Identification of Interaction between Various Beta-Amyloid Isoforms and RAGE Receptor.

Authors:  Anna P Tolstova; Alexei A Adzhubei; Vladimir A Mitkevich; Irina Yu Petrushanko; Alexander A Makarov
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.